Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
12 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Alaunos Therapeutics, Inc.’s names, not what it holds today.
Patents granted
12
12 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
27
2 of them in 2025
Names they are printed under
3
a former name, its own name
By yearGrantedApplications published
'07'08'10'11'12'13'14'15'16'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name3 counted
ZIOPHARM Oncology, Inc. a former name
US, as the owner printed on each patent
18 publishedAlaunos Therapeutics, Inc. its own name
US, as the owner printed on each patent
5 publishedZiopharm Oncology, Inc. a former name
named as the applicant on its applications, in US
4 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| May 24, 2016 | 9,346,836 | Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents | Pharmaceuticals | ZIOPHARM Oncology, Inc. |
| May 17, 2016 | 9,340,563 | Salts of isophosphoramide mustard and analogs thereof | Pharmaceuticals | ZIOPHARM Oncology, Inc. |
| Feb 9, 2016 | 9,254,298 | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof | Organic fine chemistry | ZIOPHARM Oncology, Inc. |
| Sep 29, 2015 | 9,145,431 | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof | Organic fine chemistry | ZIOPHARM Oncology, Inc. |
| Aug 5, 2014 | 8,796,329 | Method for controlling angiogenesis in animals | Pharmaceuticals | ZIOPHARM Oncology, Inc. |
| Mar 4, 2014 | 8,664,201 | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof | Organic fine chemistry | ZIOPHARM Oncology, Inc. |
| Dec 10, 2013 | 8,604,007 | Salts of isophosphoramide mustard and analogs thereof | Pharmaceuticals | ZIOPHARM Oncology, Inc. |
| Dec 18, 2012 | 8,334,398 | Compounds and methods for the treatment of cancer | Pharmaceuticals | ZIOPHARM Oncology, Inc. |
| Aug 28, 2012 | 8,252,773 | Combination therapy with organic arsenicals | Pharmaceuticals | ZIOPHARM Oncology, Inc. |
| Jun 28, 2011 | 7,968,738 | Compounds and methods for the treatment of cancer | Pharmaceuticals | ZIOPHARM Oncology, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jul 3, 2025 | 2025/0216381 | Methods for Identifying Neoantigen-Reactive T Cell Receptors | Biotechnology | Alaunos Therapeutics, Inc. |
| May 8, 2025 | 2025/0145950 | Methods for Activation and Expansion of T Cells | Biotechnology | Alaunos Therapeutics, Inc. |
| Sep 26, 2024 | 2024/0316199 | Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof | Biotechnology | Alaunos Therapeutics, Inc. |
| May 30, 2024 | 2024/0175047 | Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof | Biotechnology | Alaunos Therapeutics, Inc. |
| Dec 14, 2023 | 2023/0399370 | METHODS OF TREATING GLIOBLASTOMA | Pharmaceuticals | Alaunos Therapeutics, Inc. |
| Jul 28, 2016 | 2016/0215005 | SYNTHESIS AND FORMULATIONS OF SALTS OF ISOPHOSPHORAMIDE MUSTARD AND ANALOGS THEREOF | Organic fine chemistry | Ziopharm Oncology, Inc. |
| Nov 19, 2015 | 2015/0328238 | SYNTHESIS AND FORMULATIONS OF SALTS OF ISOPHOSPHORAMIDE MUSTARD AND ANALOGS THEREOF | Organic fine chemistry | Ziopharm Oncology, Inc. · patent 9,254,298 granted from it |
| Jun 4, 2015 | 2015/0152125 | SALTS OF ISOPHOSPHORAMIDE MUSTARD AND ANALOGS THEREOF AS ANTI-TUMOR AGENTS | Pharmaceuticals | Ziopharm Oncology, Inc. · patent 9,346,836 granted from it |
| Dec 25, 2014 | 2014/0378704 | SYNTHESIS AND FORMULATIONS OF SALTS OF ISOPHOSPHORAMIDE MUSTARD AND ANALOGS THEREOF | Organic fine chemistry | ZIOPHARM Oncology, Inc. · patent 9,145,431 granted from it |
| Jul 31, 2014 | 2014/0212495 | NANOPARTICULATE COMPOSITIONS OF TUBULIN INHIBITOR COMPOUNDS | Pharmaceuticals | ZIOPHARM Oncology, Inc. |
What it applied for, 2024 to 2025: Biotechnology 4.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.